Compare C3.ai Inc (AI) vs Cardinal Health Inc (CAH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
C3.ai Inc vs Cardinal Health Inc — how do they compare? C3.ai Inc trades at $10.48 (market cap $1.65B), while Cardinal Health Inc trades at $240 (market cap $55.88B). The key difference: Cardinal Health Inc is far larger — about 33.9× C3.ai Inc's market cap, and Cardinal Health Inc pays a 0.86% dividend while C3.ai Inc pays none. Which is the better fit depends on your goals.
| AI | CAH | |
|---|---|---|
Market Cap | $1.65B | $55.88B |
Sector | Technology | Health |
52-Week High | $19.66 | $240.26 |
52-Week Low | $7.76 | $146.04 |
Enterprise Value | $1.08B | $59.91B |
Dividend Yield | — | 0.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
C3.ai (AI) trades at $10.40, up 1.76% with a bullish technical signal despite negative profitability metrics. The company reported Q1 2026 earnings beat but maintains negative net margins of -187.95%. Recent news highlights C3.ai being named a leader in AI platforms by Forrester Research, while technical indicators show RSI levels near 90 suggesting overbought conditions.
The stock faces significant fundamental challenges with persistent losses and negative cash flow, though revenue growth and leadership positioning in enterprise AI provide long-term potential. Analyst consensus is mixed with a $10.20 price target, indicating cautious optimism amid execution risks and competitive pressures in the AI software market.
Cardinal Health (CAH) trades at $237.18, up 0.33% on the day, near its 52-week high. The stock shows bullish technical signals with consistent earnings beats, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue reached $222.58 billion in 2025, with net income margin improving to 0.67%. Positive sentiment is driven by strong Q4 2026 results and optimistic fiscal 2027 guidance highlighted by Reuters on August 11, 2026.
Outlook remains favorable with analyst consensus price target of $266.43 implying 12% upside. Key opportunities include pharmaceutical segment strength and dividend payments, while risks involve high debt levels and thin profit margins. The bullish analyst stance (54.55% buy ratings) supports growth potential, but investors should monitor cash flow volatility and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About C3.ai Inc
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →
